NCT05284851View on ClinicalTrials.gov

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

PHASE2UnknownINTERVENTIONAL
Enrollment

2,520

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

May 1, 2022

Study Completion Date

October 1, 2022

Conditions
Influenza Prevention
Interventions
BIOLOGICAL

Live Attenuated Influenza Vaccine(non freeze-dried)

Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.

BIOLOGICAL

Live Attenuated Influenza Vaccine(freeze-dried)

Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.

BIOLOGICAL

Live Attenuated Influenza Vaccine placebo

Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.

Trial Locations (1)

050021

Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang

Sponsors
All Listed Sponsors
collaborator

He Bei province Center for Disease control and prevention

UNKNOWN

lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT05284851 - The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine | Biotech Hunter | Biotech Hunter